Palvella Highlights QTORIN Rapamycin Progress in New Presentation

Palvella Therapeutics ( (PVLA) ) has provided an announcement.

On January 29, 2026, Palvella Therapeutics posted a new corporate presentation outlining progress on its late-stage pipeline and highlighting QTORIN 3.9% rapamycin anhydrous gel as a potential first FDA-approved, first-line standard-of-care therapy for both microcystic lymphatic malformations and cutaneous venous malformations, collectively representing more than 100,000 diagnosed U.S. patients and an estimated $1–$3 billion-plus peak U.S. sales opportunity. The company reported that 2025 milestones, including positive Phase 2 data in cutaneous venous malformations and completion of enrollment in the Phase 3 SELVA trial in microcystic lymphatic malformations, have set up a catalyst-rich 2026, with topline Phase 3 data in March 2026, an NDA filing for QTORIN rapamycin in the second half of 2026, and multiple additional QTORIN-based programs entering Phase 2 or pivotal studies as Palvella pursues its vision of an enduring rare disease franchise with 10 or more first-in-disease therapies in late-stage development or on the market.

The most recent analyst rating on (PVLA) stock is a Buy with a $93.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.

Spark’s Take on PVLA Stock

According to Spark, TipRanks’ AI Analyst, PVLA is a Neutral.

The score is held back primarily by weak financial performance (no recent revenue, ongoing losses, and persistent cash burn), partially offset by a stronger, low-debt balance sheet. Technically, the stock has a constructive longer-term trend with neutral momentum, while valuation remains difficult to assess given a negative P/E and no dividend yield data.

To see Spark’s full report on PVLA stock, click here.

More about Palvella Therapeutics

Palvella Therapeutics is a rare disease biopharmaceutical company focused on developing and commercializing first-in-disease therapies for serious, rare skin diseases and vascular malformations. Leveraging its proprietary QTORIN topical drug-delivery platform and an “innovative capital efficient” business model, the company is targeting multi-billion dollar, previously untreated orphan disease markets including microcystic lymphatic malformations, cutaneous venous malformations, clinically significant angiokeratomas and disseminated superficial actinic porokeratosis, under a leadership team experienced in rare disease development, regulation and product launches.

Average Trading Volume: 255,064

Technical Sentiment Signal: Hold

Current Market Cap: $993.9M

Learn more about PVLA stock on TipRanks’ Stock Analysis page.